198 related articles for article (PubMed ID: 1542858)
1. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
2. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
3. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
5. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
10. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
11. Effects of human recombinant interleukin 2 on in vitro tumor cytotoxicity in dogs.
Raskin RE; Holcomb CS; Maxwell AK
Am J Vet Res; 1991 Dec; 52(12):2029-32. PubMed ID: 1789517
[TBL] [Abstract][Full Text] [Related]
12. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
13. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
15. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
[TBL] [Abstract][Full Text] [Related]
16. [Augmentation of cytotoxicity of nonparenchymal cell of the liver after continuous IL-2 administration via the portal vein].
Shimoda K; Oka M; Hazama S; Suzuki M; Lizuka N; Wadamori K; Wang F; Suzuki T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1567-9. PubMed ID: 8373220
[TBL] [Abstract][Full Text] [Related]
17. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
18. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
19. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
20. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]